Evidence map›Paper›PMID 31002318›Full record

ArticleJAMA network open2019

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma.

Sylvain Lamure, Camille Carles, Quam Aquereburu, Philippe Quittet, Emmanuelle Tchernonog, Franciane Paul, Eric Jourdan, Agathe Waultier, Christine Defez, Ihssen Belhadj and 9 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Sylvain LamureDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Camille CarlesInstitute of Public Health, Epidemiology, and Development, University of Bordeaux, Bordeaux, France.
Quam AquereburuDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Philippe QuittetDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Emmanuelle TchernonogDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Franciane PaulDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Eric JourdanHematology Federation of University Hospitals of Montpellier and Nîmes, University of Montpellier, Montpellier, France.
Agathe WaultierHematology Federation of University Hospitals of Montpellier and Nîmes, University of Montpellier, Montpellier, France.
Christine DefezDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, Nîmes University Hospital, University of Montpellier, Montpellier, France.
Ihssen BelhadjDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, Nîmes University Hospital, University of Montpellier, Montpellier, France.
Laurence SanhesDepartment of Clinical Hematology, Perpignan General Hospital, Perpignan, France.
Sara BurcheriDepartment of Clinical Hematology, Perpignan General Hospital, Perpignan, France.
Daniel DonadioClinique du Parc, Castelneau-Le-Lez, Montpellier, France.
Carole ExbrayatClinique du Parc, Castelneau-Le-Lez, Montpellier, France.
Alain SaadDepartment of Clinical Hematology, Béziers General Hospital, Béziers, France.
Jean-Luc LaboureyDepartment of Clinical Oncology, Carcassonne General Hospital, Carcassonne, France.
Isabelle BaldiInstitute of Public Health, Epidemiology, and Development, University of Bordeaux, Bordeaux, France.
Guillaume CartronDepartment of Clinical Hematology, Montpellier University Hospital, Montpellier, France.
Pascale Fabbro-PerayDepartment of Biostatistics, Clinical Epidemiology, Public Health, and Innovation in Methodology, Nîmes University Hospital, University of Montpellier, Montpellier, France.
Université de Montpellier · FRCentre Hospitalier de Perpignan · FRCentre Hospitalier Universitaire de Montpellier · FRUniversité de Bordeaux · FRCentre Hospitalier de Béziers · FRUniversité de Nîmes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Professional use of pesticides is a risk factor for non-Hodgkin lymphoma. The main biological mechanisms of pesticides and chemotherapy are genotoxicity and reactive oxygen species generation. Cellular adaptation among patients exposed to low doses of genotoxic and oxidative compounds might hinder chemotherapy efficiency in patients with lymphoma. Objective: To examine the association of occupational exposure to pesticides with immunochemotherapy response and survival among patients treated for diffuse large B-cell lymphoma. Design, Setting, and Participants: This retrospective cohort study assessed patients treated from July 1, 2010, to May 31, 2015, for diffuse large B-cell lymphoma, with a 2-year follow-up. The study took place at 6 university and nonuniversity hospitals in Languedoc-Roussillon, France. A total of 404 patients with newly diagnosed diffuse large B-cell lymphoma treated with anthracycline-based immunochemotherapy were included before the study began. Occupational history was reconstructed for 244 patients and analyzed with the PESTIPOP French job-exposure matrix to determine likelihood of occupational exposure to pesticides. Analysis of the data was performed from July 15, 2017, to July 15, 2018. Main Outcomes and Measures: Treatment failure (ie, partial response, stable disease, disease progression, or interruption for toxic effects) rate, 2-year event-free survival, and overall survival between exposed and nonexposed patients after adjustment for confounding factors. Results: A total of 244 patients (mean [SD] age, 61.3 [15.2] years; 153 [62.7%] male) had complete occupational data. Of these patients, 67 (27.4%) had occupational exposure to pesticides, with 38 exposed through agricultural occupations. Occupational exposure was not associated with clinical and biological characteristics at diagnosis. Occupationally exposed patients had a significantly higher treatment failure rate (22.4% vs 11.3%; P = .03; adjusted odds ratio [AOR] for confounding factors, 3.0; 95% CI, 1.3-6.9); this difference was higher among patients with exposing agricultural occupations compared with other patients (29.0% vs 11.7%; AOR, 5.1; 95% CI, 2.0-12.8). Two-year event-free survival was 70% in the occupationally exposed group vs 82% in the unexposed group (adjusted hazard ratio [AHR] for confounding factors, 2.2; 95% CI, 1.3-3.9). Among patients with exposing agricultural occupations compared with other patients, the difference was more pronounced (2-year event-free survival, 56% vs 83%; AHR, 3.5; 95% CI, 1.9-6.5). Similarly, 2-year overall survival was lower in the group of patients with exposing agricultural occupations compared with other patients (81% vs 92%; AHR, 3.9; 95% CI, 1.5-10.0). Conclusions and Relevance: This retrospective study showed that agricultural occupational exposure to pesticides was associated with treatment failure, event-free survival, and overall survival among patients with diffuse large B-cell lymphoma.

Indexed as

AgedAgricultureDisease-Free SurvivalFemaleHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOccupational DiseasesOccupational ExposureOdds RatioPesticidesProportional Hazards ModelsRetrospective StudiesRisk FactorsPesticides

Identifiers

PMID31002318
PMCPMC6481431
OpenAlexW2936309846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.